Stock futures are trending lower, signaling a potential end to the S&P 500’s longest winning streak in two decades. This downturn follows President Donald Trump’s announcement of a 100% tariff on foreign-made movies, citing national security concerns. The move has impacted media stocks.
In the commodities market, Brent crude oil prices have declined by 1.%, driven by reports of planned OPEC+ production increases, while gold has risen more than 2%, driven by a weaker dollar and increased safe-haven demand amid new tariffs.
In the bond market, the yield on the 10-year U.S. Treasury has fallen to 4.301%, reflecting increased demand for safer assets amid market volatility.
Investors are awaiting the Federal Reserve’s policy decision later this week, with expectations that interest rates will remain unchanged. Additionally, key earnings reports from companies like Palantir, Disney, and Shopify are anticipated.
In pre-market trading, S&P 500 futures fell 0.78%, Nasdaq futures fell 0.98% and Dow futures fell 0.63%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly.
HIGHER –
- Skechers (SKX) up 25% after agreeing to be acquired by 3G capital for $63.00 per share in cash
- Howard Hughes (HHH) up 7% after the company and Pershing Square announced an agreement pursuant to which Pershing Square invested $900M to acquire 9M newly issued shares of Howard Hughes
UP AFTER EARNINGS –
- BioCryst (BCRX) up 9%
- Axsome Therapeutics (AXSM) up 4%
- Twist Bioscience (TWST) up 4%
- JBT Marel (JBTM) up 3%
DOWN AFTER EARNINGS –
- Integra LifeSciences (IART) down 12%
- Ocular Therapeutix (OCUL) down 9%
- TG Therapeutics (TGTX) down 7%
- Tyson Foods (TSN) down 2%
- Henry Schein (HSIC) down 1%
LOWER –
- Berkshire Hathaway (BRK.A) down 3% after chairman and CEO Warren Buffet announced that he was going to recommend to the board of directors that Greg Abel, Berkshire’s vice chairman non-insurance operations, be appointed Berkshire’s CEO to become effective on January 1, 2026
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics reports Q1 EPS 3c, consensus 17c
- Positive Revenue Outlook and Strategic Investments Reinforce Buy Rating for TG Therapeutics
- Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections
- TG Therapeutics announces data presentations for BRIUMVI at AAN 2025 Meeting
- TG Therapeutics announces two publications highlighting BRIUMVI